Can we stop this arthritis drug without relapse? new trial aims to find out

NCT ID NCT06037460

Ongoing Disease control Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at the best way to stop tocilizumab in people with giant cell arteritis, a type of blood vessel inflammation. About 120 participants will either stop the drug suddenly or taper it slowly over time. The goal is to see which approach leads to fewer relapses and allows patients to use less steroids.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tocilizumab
What this could lead to: If successful, this could provide a safe way to stop tocilizumab without increasing relapse risk, reducing treatment burden and side effects for patients with giant cell arteritis.
What could go wrong: This is a phase 3 trial but only tests discontinuation strategies, not a new treatment. Relapse risk after stopping tocilizumab is known to be around 40%, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Giant Cell Arteritis temporal arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GIANT CELL ARTERITIS

Contacts and locations

Locations

Chu Dijon Bourgogne

Dijon, 21000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.